HSIC at a glance
Henry Schein (HSIC, SEC CIK 1000228) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 22, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 27, 2025 (FY2025), Henry Schein (HSIC) reported revenue of $13.2 billion (up 4.0% from FY2024) and net income of $398.0 million. Diluted EPS was $3.27.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Henry Schein (HSIC) shares worth $4.3 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DANIEL WILLIAM K on May 11, 2026 of 10,000 shares at $69.19 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.2B
- +4.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 36 funds
- $4.3B · +1 vs prior quarter
- Latest 8-K
- Sep 22, 2026
- Item 2.03 · Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 27, 2025
Risk Factors
- CEO Stanley Bergman retiring March 1, 2026 after 37-year tenure; successor Frederick Lowery appointed January 2026 amid intensifying senior management competition
- October 2023 cyberattack disrupted North American and European distribution operations; residual financial impact persisted through 2024 with ongoing remediation costs
- KKR strategic investment of $250M at ~$76.10/share; ownership limit raised to 19.9%, creating potential conflicts via KKR investments in customers, suppliers, or competitors
- False Claims Act exposure: whistleblower relators entitled to up to 30% of government recoveries; penalties include treble damages plus potential Medicare/Medicaid exclusion
- Top 10 Global Distribution suppliers represent ~24% of aggregate purchases; no long-term contracts, creating supply disruption risk for high-margin products
Business Overview
- Global distribution of dental/medical products and services to office-based practitioners, supplemented by specialty products and healthcare technology software
- Global Technology fastest-growing segment at +7.1% driven by cloud-based practice management platform adoption and revenue cycle management solutions; launched Global E-Commerce Platform (henryschein.com)
- Active 2024 restructuring plan (completing 2027) reshaping portfolio via business disposals across all three segments; $105M charges in FY2025 vs $73M in FY2024
- Net sales $13.2B, up 4.0% YoY; share count fell from 124M to 116M as company repurchased $250M via accelerated buyback plus new $750M repurchase authorization
- Total debt surged to $3.1B from $2.5B YoY while operating cash flow declined $136M to $712M; $36M in shareholder advisory/consulting costs flagged as unusual adjustment vs just $2M prior year
Management Discussion & Analysis
- Revenue $13,184M in FY2025, up 4.0% YoY from $12,673M; internal growth 2.6%, acquisitions 0.9%, FX 0.5%
- Gross margin 31.1% vs 31.7% prior year; operating expense ratio 26.2% vs 26.8%; effective tax rate 23.7% vs 24.9%
- Best segment: Global Technology +7.1% sales, gross margin 67.7% vs 67.4%; worst: Global Distribution gross margin 25.0% vs 25.8%
- Operating cash flow $712M vs $848M; investing cash outflow $400M; $250M accelerated share repurchase executed May 2025; $780M remaining buyback capacity; total debt $3,107M vs $2,536M
- Key risks: OBBBA Medicaid cuts and tariffs flagged as likely adverse to utilization and costs; restructuring charges $105M in FY2025 with plan continuing through end of 2027
AI summary of the HSIC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 27, 2026
Management Discussion & Analysis
- Revenue $3,458M, up $218M or 6.7% YoY from $3,240M
- Global Specialty Products best-performing segment, sales $419M, up 8.7% YoY
- Global Medical weakest major product line, sales $1,057M, up 4.0% YoY
- Operating income $171M vs $151M YoY; restructuring charges $29M vs $23M
- Operating cash flow $145M vs $157M; investing outflow $128M vs $197M
Risk Factors
- No material changes to 10-K risk factors for year ended December 27, 2025
- Carried-forward risks remain the most significant disclosed exposures
- Share repurchases reduced available authorization to $455 million as of June 27, 2026
- 10-Q provides no newly triggered regulatory, legal, operational, competitive, or financial risk factors
AI summary of the HSIC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 references an off-balance-sheet arrangement, indicating a potential financial obligation outside the reported balance sheet
- Investors should review the referenced disclosure for commitment size, counterparties, terms, and possible liquidity impact
Item 1.01: Entry into a Material Definitive Agreement
- Revolving credit capacity increased from $1 billion to $1.25 billion, expanding liquidity by $250 million
- Maturity extended to September 19, 2031, reducing near-term refinancing pressure
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, with earnings information incorporated by reference
- No operating results or financial figures included in the provided filing text
Item EX-99.1: Item EX-99.1
- Q2 sales $3.458B, up 6.7%, with 4.6% internal growth; broad-based momentum reduces reliance on acquisitions
- Non-GAAP diluted EPS $1.27, up 15.5%; Adjusted EBITDA $288M versus $256M, signaling operating leverage
Item 7.01: Regulation FD Disclosure
- Leadership transitions disclosed under Regulation FD, signaling potential changes in strategic execution and operating priorities
- Exhibit 99.1 contains the press release and substantive details on affected executives and transition timing
Item 5.02: Departure/Appointment of Directors or Principal Officers
- COO Michael S. Ettinger transitioning to senior advisory role effective October 30, 2026
- Chief Strategic Officer Mark E. Mlotek transitioning to senior advisory role on the same date
Item EX-99.1: Item EX-99.1
- New Henry Schein Leadership Team replaces Executive Management Committee, targeting faster decisions and simpler operations
- Global supply chain organization integrated with distribution group, potentially improving customer coordination and execution
AI summaries of HSIC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HSIC
Don't miss the next HSIC filing
- Alerts as it files. A push when HSIC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HSIC, by share count.
- Ask anything. An AI agent that reads every HSIC filing and answers with sources.
HSIC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Albertini Andrea | D | Sep 8, 2026 | 3,984 | - |
| Albertini Andrea | F | Sep 8, 2026 | 603 | $88.86 |
| DANIEL WILLIAM K | A | Jun 12, 2026 | 2,215 | - |
| BERGMAN STANLEY M | G | May 26, 2026 | 50 | - |
| BERGMAN STANLEY M | G | May 21, 2026 | 50 | - |
| BERGMAN STANLEY M | G | May 19, 2026 | 1,040 | - |
| DANIEL WILLIAM K | Buy | May 11, 2026 | 10,000 | $69.19 |
| Popeck Thomas C | Sell | Mar 19, 2026 | 1,355 | $72.79 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $12.7B | $13.2B |
| Gross Profit | - | $4.0B | $4.1B |
| Operating Income | $615.0M | $621.0M | $653.0M |
| Net Income | $416.0M | $390.0M | $398.0M |
| Gross Margin | - | 31.7% | 31.1% |
| Op. Margin | - | 4.9% | 5.0% |
| Net Margin | - | 3.1% | 3.0% |
| Balance Sheet | |||
| Total Assets | - | $10.2B | $11.2B |
| Equity | - | $3.4B | $3.2B |
| ROE | - | 11.5% | 12.3% |
| Per Share | |||
| EPS | $3.16 | $3.05 | $3.27 |
| Cash Flow | |||
| Operating CF | $500.0M | $848.0M | $712.0M |
Source: XBRL data in Henry Schein (HSIC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HSIC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $4.28B |
| Q1 2026 | 35 | $3.59B |
| Q4 2025 | 33 | $3.68B |
| Q3 2025 | 36 | $3.79B |
| Q2 2025 | 33 | $3.78B |
| Q1 2025 | 31 | $2.98B |
| Q4 2024 | 28 | $2.47B |
| Q3 2024 | 22 | $1.21B |
- Citadel Advisors LLC+2.89M (+8703%)
- FMR LLC (Fidelity)+1.83M (+32%)
- Morgan Stanley+674.1K (+47%)
- Dimensional Fund Advisors+521.2K (+18%)
- Goldman Sachs Group+342.3K (+41%)
- Invesco Ltd−1.74M (-36%)
- Ameriprise Financial−1.56M (-86%)
- JPMorgan Chase & Co−219.6K (-5%)
- Millennium Management−161.9K (-98%)
- Vanguard Capital Management LLC−76.5K (-1%)
- HANCOCK WHITNEY CORP+116.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 254 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HSIC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | May 26, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 28, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
Related Health Care companies
- ACH · ACCENDRA HEALTH INC/VA/Wholesale-Medical, Dental & Hospital Equipment & Supplies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
HSIC SEC filings: frequently asked questions
Which institutions hold HSIC stock?
As of June 30, 2026, the largest Henry Schein (HSIC) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($630.9 million), BlackRock ($586.7 million), Vanguard Capital Management LLC ($530.1 million), JPMorgan Chase & Co ($366.4 million), State Street Corp ($359.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HSIC's revenue in fiscal year 2025?
For the fiscal year ended December 27, 2025 (FY2025), Henry Schein (HSIC) reported revenue of $13.2 billion (up 4.0% from FY2024) and net income of $398.0 million. Diluted EPS was $3.27. The figures come from the XBRL data in the 10-K.
What are the main risks in HSIC's latest 10-K?
In the 10-K filed February 24, 2026, Henry Schein (HSIC) flagged: CEO Stanley Bergman retiring March 1, 2026 after 37-year tenure; successor Frederick Lowery appointed January 2026 amid intensifying senior management competition. October 2023 cyberattack disrupted North American and European distribution operations; residual financial impact persisted through 2024 with ongoing remediation costs. (AI summary of the Risk Factors section.)
What did HSIC report in its latest 8-K?
Henry Schein (HSIC) filed an 8-K on September 22, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation) and Item 1.01 (Entry into a Material Definitive Agreement). Item 2.03 references an off-balance-sheet arrangement, indicating a potential financial obligation outside the reported balance sheet.
What are the latest HSIC SEC filings?
Henry Schein (HSIC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 22, 2026 and a Form 4 insider filing on September 9, 2026.
What is HSIC's SEC CIK number?
Henry Schein (HSIC)'s SEC Central Index Key (CIK) is 1000228. EDGAR lists every HSIC filing under that number.
Ask anything about HSIC
The research agent reads HSIC's filings, financials, insider trades and 13F holders, then answers with sources.